Literature DB >> 15996702

Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system.

Ian C Brett1, Bert E Johansson.   

Abstract

To simulate the 2003-2004 influenza season and compare available vaccination methods, immunologically naive mice were immunized with: influenza A virus hemagglutinin (rHA) and neuraminidase (rNA) from A/Panama/2007/99 H3N2 or A/Fujian/411/2002 H3N2 expressed by recombinant baculovirus, chromatographically purified, either as single antigens (rHA or rNA) or in combination (rHArNA); conventional inactivated monovalent (CIV) vaccines from each heterotypic strain; or a live-attenuated influenza (LAV) vaccine derived from the A/Panama/2007/99 strain. HA containing vaccines were highly immunogenic for the HA antigen, with no statistically significant differences among groups in the amount of homotypic anti-HA antibody induced. Little cross-reactive anti-HA antibody was induced by any vaccine, including LAV. Statistically, the greatest amount of anti-NA antibody was induced by the purified NA alone or in combination with purified HA; the least amount of anti-NA antibody was found in mice immunized with LAV or CIV. Immunization with vaccines immunogenic for both HA and NA resulted in an immune response to both surface glycoproteins that suppressed homotypic, closely related heterotypic infection and had a greater reduction in mPVT following an infectious challenge by a distantly related heterotypic strain. These studies suggest that vaccines immunogenic for both HA and NA offer an increased level of protection from influenza.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15996702     DOI: 10.1016/j.virol.2005.06.006

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  34 in total

1.  Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses.

Authors:  Matthew R Sandbulte; Kim B Westgeest; Jin Gao; Xiyan Xu; Alexander I Klimov; Colin A Russell; David F Burke; Derek J Smith; Ron A M Fouchier; Maryna C Eichelberger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-05       Impact factor: 11.205

2.  Evaluation of antibody response in mice against avian influenza A (H5N1) strain neuraminidase expressed in yeast Pichia pastoris.

Authors:  Murugan Subathra; Ponsekaran Santhakumar; Mangamoori Lakshmi Narasu; Syed Sultan Beevi; Sunil K Lal
Journal:  J Biosci       Date:  2014-06       Impact factor: 1.826

3.  Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.

Authors:  Gale E Smith; Xiangjie Sun; Yaohui Bai; Ye V Liu; Michael J Massare; Melissa B Pearce; Jessica A Belser; Taronna R Maines; Hannah M Creager; Gregory M Glenn; David Flyer; Peter Pushko; Min Z Levine; Terrence M Tumpey
Journal:  Virology       Date:  2017-06-16       Impact factor: 3.616

4.  Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets.

Authors:  Berend Jan Bosch; Rogier Bodewes; Robert P de Vries; Joost H C M Kreijtz; Willem Bartelink; Geert van Amerongen; Guus F Rimmelzwaan; Cornelis A M de Haan; Albert D M E Osterhaus; Peter J M Rottier
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

5.  Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.

Authors:  Lianlian Jiang; Giovanna Fantoni; Laura Couzens; Jin Gao; Ewan Plant; Zhiping Ye; Maryna C Eichelberger; Hongquan Wan
Journal:  J Virol       Date:  2015-10-14       Impact factor: 5.103

6.  Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.

Authors:  Lisa Walz; Sarah-Katharina Kays; Gert Zimmer; Veronika von Messling
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

7.  Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin.

Authors:  William C Weldon; Bao-Zhong Wang; Maria P Martin; Dimitrios G Koutsonanos; Ioanna Skountzou; Richard W Compans
Journal:  PLoS One       Date:  2010-09-01       Impact factor: 3.240

8.  Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus.

Authors:  Victor C Huber; Loren H Kleimeyer; Jonathan A McCullers
Journal:  Vaccine       Date:  2008-08-15       Impact factor: 3.641

Review 9.  Virus-like particles as universal influenza vaccines.

Authors:  Sang-Moo Kang; Min-Chul Kim; Richard W Compans
Journal:  Expert Rev Vaccines       Date:  2012-08       Impact factor: 5.217

10.  Induction of long-term protective immune responses by influenza H5N1 virus-like particles.

Authors:  Sang-Moo Kang; Dae-Goon Yoo; Aleksandr S Lipatov; Jae-Min Song; C Todd Davis; Fu-Shi Quan; Li-Mei Chen; Ruben O Donis; Richard W Compans
Journal:  PLoS One       Date:  2009-03-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.